Y Mabs Therapeutics Stock Performance
| YMAB Stock | USD 11.88 1.11 10.31% |
The firm maintains a market beta of 1.32, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Y MAbs will likely underperform. At this point, Y mAbs Therapeutics has a negative expected return of -0.18%. Please make sure to check out Y MAbs' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Y mAbs Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Y mAbs Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 10.31 | Five Day Return 17.74 | Year To Date Return 72.93 | Ten Year Return (50.50) | All Time Return (50.50) |
1 | Disposition of 65000 shares by Thomas Gad of Y MAbs at 13.47 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of 30000 shares by Thomas Gad of Y MAbs at 12.97 subject to Rule 16b-3 | 09/16/2024 |
3 | Disposition of 22831 shares by Thomas Gad of Y MAbs at 4.38 subject to Rule 16b-3 | 09/19/2024 |
4 | Insider Trading | 09/27/2024 |
5 | Disposition of 722 shares by Ber Gerard of Y MAbs at 12.0 subject to Rule 16b-3 | 10/04/2024 |
6 | Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast | 10/25/2024 |
7 | Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA in Japan | 11/04/2024 |
8 | What To Expect From Y-mAbs Therapeutics Inc Q3 2024 Earnings | 11/07/2024 |
9 | Paradigm Biocapital Advisors LP Bolsters Position in Y-mAbs Therapeutics Inc | 11/15/2024 |
10 | The Market Doesnt Like What It Sees From Y-mAbs Therapeutics, Inc.s Revenues Yet As Shares Tumble 26 | 11/19/2024 |
11 | Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement | 11/22/2024 |
| Begin Period Cash Flow | 105.8 M |
YMAB |
Y MAbs Relative Risk vs. Return Landscape
If you would invest 1,388 in Y mAbs Therapeutics on August 31, 2024 and sell it today you would lose (200.00) from holding Y mAbs Therapeutics or give up 14.41% of portfolio value over 90 days. Y mAbs Therapeutics is currently does not generate positive expected returns and assumes 3.787% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than YMAB, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Y MAbs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Y MAbs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Y mAbs Therapeutics, and traders can use it to determine the average amount a Y MAbs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0463
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | YMAB |
Estimated Market Risk
| 3.79 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Y MAbs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Y MAbs by adding Y MAbs to a well-diversified portfolio.
Y MAbs Fundamentals Growth
YMAB Stock prices reflect investors' perceptions of the future prospects and financial health of Y MAbs, and Y MAbs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on YMAB Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 465.05 M | ||||
| Shares Outstanding | 44.79 M | ||||
| Price To Book | 5.76 X | ||||
| Price To Sales | 6.29 X | ||||
| Revenue | 84.82 M | ||||
| Gross Profit | 57.7 M | ||||
| EBITDA | (25.67 M) | ||||
| Net Income | (21.43 M) | ||||
| Cash And Equivalents | 133.66 M | ||||
| Cash Per Share | 3.06 X | ||||
| Total Debt | 1.42 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | 2.06 X | ||||
| Cash Flow From Operations | (27.23 M) | ||||
| Earnings Per Share | (0.54) X | ||||
| Market Capitalization | 532.09 M | ||||
| Total Asset | 127.87 M | ||||
| Retained Earnings | (457.47 M) | ||||
| Working Capital | 90.98 M | ||||
About Y MAbs Performance
By analyzing Y MAbs' fundamental ratios, stakeholders can gain valuable insights into Y MAbs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Y MAbs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Y MAbs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 161.94 | 230.59 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.24) | (0.25) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about Y mAbs Therapeutics performance evaluation
Checking the ongoing alerts about Y MAbs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Y mAbs Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Y mAbs Therapeutics generated a negative expected return over the last 90 days | |
| Y mAbs Therapeutics has high historical volatility and very poor performance | |
| Y mAbs Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 84.82 M. Net Loss for the year was (21.43 M) with profit before overhead, payroll, taxes, and interest of 57.7 M. | |
| Y mAbs Therapeutics currently holds about 133.66 M in cash with (27.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.06. | |
| Roughly 72.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from benzinga.com: Y-mAbs Omburtamab Failure The Critical Turning Point And 19.65M Shareholder Settlement |
- Analyzing Y MAbs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Y MAbs' stock is overvalued or undervalued compared to its peers.
- Examining Y MAbs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Y MAbs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Y MAbs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Y MAbs' stock. These opinions can provide insight into Y MAbs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |